Asciminib Combination Therapy

Protocol Number: HJKC3-0003. Treatment Free Remission After Combination Therapy With Asciminib (ABL001) Plus Tyrosine Kinase Inhibitors (TKI) in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Who Relapsed After a Prior Attempt at TKI Discontinuation

What's the purpose of the trial?

This is a single arm phase II study that will enroll a minimum of 47 subjects with a maximum of 51. All patients will have a confirmed diagnosis of chronic phase chronic myeloid Leukemia and must have previously attempted to discontinue Tyrosine Kinase inhibitors (TKI). All patients must have restarted the same TKI they were on prior to discontinuation at the time of relapse in order to be eligible for this trial.
Trial status

Accepting patients

Phase
Phase 2
Enrollment
51
Last Updated
3 months ago

Partner With us to Treat Your Patient's Cancer.

For referring physicians, our dedicated clinician access line can be reached Monday through Friday 8 am to 6pm (Eastern time) by dialing (888) 874-5087.

Refer a Patient PortalCall Clinician Access Line

Participating Centers

There are 3 centers participating in this trial. Enter a location below to find the closest center.

Experimental Treatments

Learn more about the experimental treatments being evaluated in this clinical trial.

  • Asciminib is a kind of drug called a tyrosine kinase inhibitor that may help to kill cancer cells in different types of cancers.
  • Dasatinib is a tyrosine kinase inhibitor being tested in multiple myeloma.
  • Imatinib (Glivec)
  • Nilotinib is a kind of drug called a tyrosine kinase inhibitor that may help to kill different types of cancer cells.

Arms / Cohorts

Explore eligibility, treatments and learn more about potential cohorts.

Accepting patients

Asciminib + Imatinib

Accepting patients

Asciminib + Nilotinib

Accepting patients

Asciminib + Dasatinib

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print Report

Print a patient-friendly report to share with your patient.

(888) 828-2206

We can help answer any questions and connect you (or your patient) with the study team.

Schedule Call

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.